In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

In vitro - in vivo - in silico approach in the development of inhaled drug products : Nanocrystal-based formulations with budesonide as a model drug. / Shi, Changzhi; Ignjatović, Jelisaveta; Liu, Tingting; Han, Meihua; Cun, Dongmei; Đuriš, Jelena; Yang, Mingshi; Cvijić, Sandra.

In: Asian Journal of Pharmaceutical Sciences, Vol. 16, No. 3, 2021, p. 350-362.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Shi, C, Ignjatović, J, Liu, T, Han, M, Cun, D, Đuriš, J, Yang, M & Cvijić, S 2021, 'In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug', Asian Journal of Pharmaceutical Sciences, vol. 16, no. 3, pp. 350-362. https://doi.org/10.1016/j.ajps.2020.12.001

APA

Shi, C., Ignjatović, J., Liu, T., Han, M., Cun, D., Đuriš, J., Yang, M., & Cvijić, S. (2021). In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. Asian Journal of Pharmaceutical Sciences, 16(3), 350-362. https://doi.org/10.1016/j.ajps.2020.12.001

Vancouver

Shi C, Ignjatović J, Liu T, Han M, Cun D, Đuriš J et al. In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug. Asian Journal of Pharmaceutical Sciences. 2021;16(3):350-362. https://doi.org/10.1016/j.ajps.2020.12.001

Author

Shi, Changzhi ; Ignjatović, Jelisaveta ; Liu, Tingting ; Han, Meihua ; Cun, Dongmei ; Đuriš, Jelena ; Yang, Mingshi ; Cvijić, Sandra. / In vitro - in vivo - in silico approach in the development of inhaled drug products : Nanocrystal-based formulations with budesonide as a model drug. In: Asian Journal of Pharmaceutical Sciences. 2021 ; Vol. 16, No. 3. pp. 350-362.

Bibtex

@article{6d0d5a0db71d46ae80cd9d04d86ff161,
title = "In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug",
abstract = "This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats{\textquoteright} lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus{\texttrademark} software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.",
keywords = "Budesonide, In silico physiologically-based pharmacokinetic modeling, Nanocrystal suspension, Nanocrystal-embedded microparticles, Pulmonary drug delivery",
author = "Changzhi Shi and Jelisaveta Ignjatovi{\'c} and Tingting Liu and Meihua Han and Dongmei Cun and Jelena {\D}uri{\v s} and Mingshi Yang and Sandra Cviji{\'c}",
year = "2021",
doi = "10.1016/j.ajps.2020.12.001",
language = "English",
volume = "16",
pages = "350--362",
journal = "Asian Journal of Pharmaceutical Sciences",
issn = "1818-0876",
publisher = "Hong Kong Asiamed Publish House",
number = "3",

}

RIS

TY - JOUR

T1 - In vitro - in vivo - in silico approach in the development of inhaled drug products

T2 - Nanocrystal-based formulations with budesonide as a model drug

AU - Shi, Changzhi

AU - Ignjatović, Jelisaveta

AU - Liu, Tingting

AU - Han, Meihua

AU - Cun, Dongmei

AU - Đuriš, Jelena

AU - Yang, Mingshi

AU - Cvijić, Sandra

PY - 2021

Y1 - 2021

N2 - This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.

AB - This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates.

KW - Budesonide

KW - In silico physiologically-based pharmacokinetic modeling

KW - Nanocrystal suspension

KW - Nanocrystal-embedded microparticles

KW - Pulmonary drug delivery

U2 - 10.1016/j.ajps.2020.12.001

DO - 10.1016/j.ajps.2020.12.001

M3 - Journal article

C2 - 34276823

AN - SCOPUS:85102878238

VL - 16

SP - 350

EP - 362

JO - Asian Journal of Pharmaceutical Sciences

JF - Asian Journal of Pharmaceutical Sciences

SN - 1818-0876

IS - 3

ER -

ID: 260424089